Work

Relieving hepatic steatosis: Another benefit of dipeptidyl peptidase-4 (DPP4) inhibitors

Year: 2015

Type: article

Abstract: Hepatic steatosis is strongly associated with type 2 diabetes (T2DM), both of which are common disorders resulting from obesity [1]. Compared to the general population, there is a higher risk for chronic liver disease and cirrhosis, arising from hepatic steatosis, in diabetic persons (2.3-fold increase of mortality in older onset [diagnosed after age 30] and 4.8-fold increase of mortality in younger onset [diagnosed before age 30]) [2]. Therefore, hepatic steatosis is a key issue in the treatment of T2DM. Furthermore in recent studies, dipeptidyl peptidase-4 (DPP4) inhibition has been suggested to ameliorate hepatic steatosis.

Source: International Journal of Hepatobiliary and Pancreatic Diseases

DOI: 10.5348/ijhpd-2015-36-ed-11

Authors: Zachary Braunstein, Jixin Zhong

Institutions: University of Maryland, Baltimore, Wright State University

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4238525270